Lu Xu

Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study

Michael Boyer, Mehmet Alı Nahıt Şendur, Delvys Rodríguez‐Abreu et al. · Journal of Clinical Oncology · 2021 · 253 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Phase I Trial and Pharmacokinetic Study of Bevacizumab in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Study

Julia Glade Bender, Peter C. Adamson, Joel M. Reid et al. · Journal of Clinical Oncology · 2008 · 251 citations

Pharmacy, Oncology, Pharmacology +16

A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors

Antonio Jimeno, Michael A. Gordon, Rashmi Chugh et al. · Clinical Cancer Research · 2017 · 204 citations

Medicine, Oncology, Pharmacology +17

Pharmacokinetics of Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration: A Population Approach

Lu Xu, Tong Lu, Lisa Tuomi et al. · Investigative Ophthalmology & Visual Science · 2013 · 199 citations

Medicine, Pharmacokinetics, Pharmacology +15

A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors

David C. Smith, Peter D. Eisenberg, Georgy M. Manikhas et al. · Clinical Cancer Research · 2014 · 158 citations · Full text

Medicine, Oncology, Pharmacology +17